NBIX Stock Neurocrine Biosciences (NBIX, $147.53) price moved above its 50-day Moving Average on December 22, 2025

GET DAILY SIGNALS

Get AI intraday signals

NBIX - Neurocrine Biosciences

Moving Avg. signal

View

Odds of UP Trend

Price: $147.53

Daily change: +$2.53 (+1.74%)

Daily volume: 694.7K

Capitalization: $14.7B

Industry: Pharmaceuticals: Generic

This price move could indicate a change in the trend, and may be a buy signal for investors. A.I.dvisor found 43 similar cases, and were successful. Based on this data, the odds of success are

NBIX in upward trend: 10-day moving average moved above 50-day moving average on November 26, 2025

The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on November 26, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where NBIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on December 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

NBIX moved below its 50-day moving average on December 26, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.822) is normal, around the industry mean (21.577). P/E Ratio (34.668) is within average values for comparable stocks, (74.473). Projected Growth (PEG Ratio) (0.360) is also within normal values, averaging (1.981). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (5.534) is also within normal values, averaging (64.586).